Savara announces resignation of chief medical officer

Austin, texas--(business wire)--savara inc. (nasdaq: svra), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that badrul chowdhury, m.d., ph.d., has resigned from his role as chief medical officer, effective september 9, 2022. “we appreciate dr. chowdhury's contributions during his tenure with the company,” said matt pauls, chair and ceo, savara. “his leadership helped progress our molgramostim nebulizer solution (molgramostim) development program
SVRA Ratings Summary
SVRA Quant Ranking